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ABSTRACT (250) 
 
 
Objectives 
 
Direct comparison of different diseases allows clinicians and researchers to place the burden of symptoms 
and impact on quality of life of each condition in context. Generic health-related quality of life  
assessment tools allow such analysis, limited data is available for British patients with Chronic 
rhinosinusitis. 
 
Design 
 
As part of a larger feasibility study, patients underwent baseline assessment using the SNOT-22, SF-12 
and EQ-5D-5L tools. Data was analysed using Microsoft excel and algorithms available for the analysis  
of the later 2 tools. We plotted EQ-5D-5L VAS and utility scores and SF-12 MCS and PCS scores 
separately against SNOT-22 scores and quantified associations using bivariate ordinary least squares 
regression analysis. 
 
Setting 
 
Patients were prospectively recruited from 6 UK outpatient clinics. 
 
 
Participants 
 
Adult patients with chronic rhinosinusitis without nasal polyps (CRSsNPs). 
 
 
Main Outcome measures 
 
Baseline SNOT-22, SF-12 and EQ-5D-5L scores. 
 
 
Results 
 
Fifty-two adults were recruited with a mean age of 55 years, 51% were male. The mean SNOT-22 score 
was 43.82. Mental and physical component scores of the SF-12 were 46.53 and 46 respectively. Mean 
  
 
 
 
 
index score computed form the EQ-5D-5L was 0.75. Worse (higher) SNOT-22 scores were associated 
with lower EQ-5D-5L VAS and utility scores and SF-12 MCS and PCS scores. 
 
Conclusion 
 
The EQ-5D-5L suggests that British CRSsNPs patients are negatively impacted with regards to quality of 
life. We found the SF-12 to be less sensitive and conclude that the EQ-5D-5L tool is a quick and 
accessible method for assessing QOL in order it can be compared with other disease states. 
  
 
 
 
 
Introduction 
 
There is accumulating evidence of the personal and societal impact of chronic rhinosinusitis (CRS) with 
regards to symptom severity 
1
, reduced productivity and absenteeism 
2
. Many studies of patients with 
CRS increasingly use the Sinonasal Outcome Test (SNOT-22) (disease specific, internationally validated 
questionnaire) as an outcome measure 
3
. While this allows for excellent assessment and monitoring of the 
impact of CRS symptoms at an individual level, it does not allow direct comparison with other chronic 
conditions. Generic health-related quality of life (HRQoL) assessment tools allow comparison of disease 
states on both a functional level 
4 
and with regards to and the burden to society each condition presents. 
Such tools include the EuroQoL Five Dimension tool (EQ-5D-3L/5L)
5
, Health Utilities Index 
6
, the Short 
Form 36 (SF-36) 
7  and the latter’s shortened versions, the SF-12 and SF-6D. 
Lange et al published health utility assessments from the trans-European GALEN study that showed a 
lower health-related quality of life using the EQ-5D-3L in CRS patients compared to those without   CRS 
8
. A recent study in the USA reported a lower health utility value (also generated by the EQ-5D) for 
 
patients with CRS compared to the general population, the value was similar to that of other chronic 
disease such as mild asthma and migraine 
9
. A large UK epidemiological study recently showed those  
with CRS to have lower QOL using the SF-36, specifically both mental health and emotional domains 
were lower 
10
.   The SF-36 was converted to a shorter form, the SF-12 and validated for use within the UK 
11
. The SF-12 has itself been used for CRS patients outside the UK
12  
and as a short and quicker method of 
 
assessing HRQoL than the SF36 it is potentially more attractive for future research. Thus, the aim of this 
study is to evaluate the EQ-5D-5L and SF-12 health utility measures in a UK CRS population. In addition 
the data can be seen alongside the widely published disease-specific SNOT-22 questionnaire. 
 
 
Methods 
 
As part of a feasibility study, a prospective cohort of patients were recruited from six UK centres with a 
confirmed diagnosis of CRS without nasal polyps (CRSsNPs) just prior to commencing maximal medical 
  
between 6.5 and 7 in published studies 
3, 8 
, 
 
 
 
 
therapy 
13
. The study was ethically approved by the West Midlands Research Ethics Committee (ref: 
12/WM/0359) and included on the UK CRN portfolio (ref: 13417). Funding was provided by a Royal 
College of Surgeons Pump Priming Grant and supported by the Anthony Long and Bernice Bibby Trusts. 
All patients recruited were diagnosed with CRSsNPs according the EPOS 2012 criteria 
14 
by a rhinologist 
in a specialist clinic and subsequently underwent 2 face-to-face study visits and a third interaction via 
postal correspondence (questionnaires and feedback only). Patients who did not complete all 
questionnaires were excluded from this analysis. Adult patients between 18 and 70 years, with a diagnosis 
of CRSsNPs as per the EPOS guidelines who had not received maximal medical treatment previously 
were included, and while previous surgery was not a reason for exclusion no patients had undergone 
previous  endoscopic  sinus  surgery.  Maximal  medical  therapy  was  considered  as  per  EPOS      2012 
 
guidelines to be alkaline nasal douches and intranasal corticosteroid preparation, longterm (12 weeks) 
antibiotics
14
. 
Patients with CRSwNPs and secondary CRS (eg Wegner’s, immunodeficiency) were excluded. Patients 
received a 12-week course of Clarithromycin 250mg b.d. alongside b.d. nasal douching and intranasal 
mometasone, (2 squirts, each nostril b.d.), the latter two being continued for a further 12 weeks. 
 
Measures 
 
The SNOT-22 is an internationally validated disease-specific questionnaire detailing both disease-specific 
(e.g. blocked nose) and global (e.g. sleep disturbance) domains
3
. Twenty-two items are covered and 
scored on a Likert grading system (0-5). The resulting scores range from 0 – 110, the median score in a 
normal population without CRS ranges . 
 
 
The SF-12 questionnaire (a condensed version of the SF-36) is a 12-point assessment tool covering eight 
dimensions of health; two validated scores are produced, the physical component summary (PCS) and the 
mental component summary (MCS) . The scores compare to a norm-based scoring algorithm where 50  is 
  
 
 
 
 
the typical adult, a score of over 50 indicates better health than the typical person and less than 50, worse 
health. 
 
The EQ-5D-5L is a standardised measure of health status consisting of a visual analogue scale (VAS) to 
assess patient reported health state on the day of completing the survey (0 = worst imaginable health state 
and 100 = best imaginable health state) in addition to a questionnaire with 5 dimensions (mobility, self- 
care, usual activities, pain/discomfort and anxiety/depression) (EuroQol 2011) 
16
. Each of the dimensions 
asks for a response that corresponds to a health status level of no problems, slight problems, moderate 
problems, severe problems, and extreme problems that are coded level 1-5 respectively. The levels can 
then converted into a health index score using the website (https://www.ohe.org/publications/valuing- 
health-related-quality-life-eq-5d-5l-value-set-england), according to the population setting (in this case 
 
UK), on a scale where 1 equals perfect health and 0 equals death, and values less than zero represent  
states worse than death. 
 
All 3 questionnaires were completed by patients at baseline, 12 weeks and 6 months, for the purpose of 
this analysis which aimed to report HRQoL for British CRS patients only baseline data is reported. 
 
Analysis 
 
All results were analysed using Microsoft excel. In addition, the EQ-5D-5L was analysed using the 
euroqol website to give an index score. 
 
We plotted EQ-5D-5L VAS and utility scores and SF-12 MCS and PCS scores separately against SNOT- 
22 scores and quantified associations using bivariate ordinary least squares regression analysis, regressing 
each measure separately against SNOT-22 scores. 
  
 
 
 
 
 
 
 
 
Results 
 
Fifty-five patients were recruited over a 13-month period (January 2013-January 2014), the mean age was 
55 years (range 21-81) and 51% were male. Following exclusions 52 patients who completed all 3 
questionnaires were included in this study. The mean SNOT-22 score was 43.82 (Standard deviation  
22.4). 
 
SF-12 scores are reported as 2 separate scores, the mental and physical component. The mean MCS was 
 
46.53 (SD of 11.46) and the mean PCS 46 (SD of 11.46), both lower than the score expected for a ‘typical 
adult’ (e.g. score of 50 or above). 
 
The EQ-5D has two components, the questionnaire given an index score and the VAS. The mean index 
score of was 0.75 (SD of 0.23). The questionnaire component is reported as the percentage of patients 
reporting a particular level within each of the 5 dimensions and is represented in table 1. The mean VAS 
score was 73.38. 
 
Worse (higher) SNOT-22 scores were associated with lower EQ-5D-5L VAS and utility scores and SF-12 
MCS and PCS scores (Figure 1). In all cases the coefficient on SNOT-22 score was statistically  
significant and negative (all four p-values on the SNOT-22 score regression coefficient<0.05). 
 
 
Discussion 
 
Synopsis of key/new findings with comparison with other studies 
 
This is the first publication of EQ-5D and SF12 scores in UK patients diagnosed with CRSsNPs in 
accordance to the EPOS-2012 guidelines. The mean SNOT-22 score in this study is comparable to other 
larger published cohorts of patients with CRSsNP undergoing medical treatment in a hospital setting, and 
therefore our results are likely to be generalisable to CRS patients referred for ENT treatment across the 
UK. 
  
 
 
 
 
Using the norm-based scoring system published by the developers of the SF-12 (where the mean score in 
the general population is 50 with a standard deviation of 10 in the USA general population) both physical 
(self-care, physical and social activities alongside bodily pain and tiredness) component score (46.53) and 
mental (psychological distress) component summary scores (46) are both reduced. Compared to values   
for a British population with ‘No reported chronic illness’ (scores of 52.08 (PCS) and 51.60 (MCS) 17, the 
scores are notably lower and similar to previously reported CRS studies 46.7 and 45.6 (PCS and MCS 
respectively, USA population) 
18
. 
Overall the SF-12 scores suggest that despite their CRS, patients manage relatively well with regards to 
both physical and mental quality of life components when compared to other chronic diseases (see table 
2). The findings from this study are in contrast with work by Glicklich et al 
19 
and Erskine et al 
10 
who 
used the full SF-36. In the later study overall scores were reduced in CRS patients when compared to non- 
CRS controls, with a difference of 11-17 points (p<0.001) for overall quality of life. In their study, a 
significant difference was also found when looking at the mental and emotional health domains; those 
with CRS scored more negatively than those without, with those with CRSsNPs scoring more poorly than 
those with nasal polyps. Qualitative interviews have also found significant negative quality of life related 
issues . There are several reasons for the discrepancy; it may be that the SF-12 lacks the sensitivity to 
detect the impact of CRS on the HRQoL of the patient, as the tool focuses largely on physical activity and 
mobility. One common problem for patients relating to quality of life is known to be accessing  
appropriate treatment, and the feeling that symptoms are not taken seriously hence there may therefore be 
benefit for the patients in the trial in knowing they are receiving treatment while taking part in a trial. 
Additionally concurrent asthma contributes negatively on quality of life in CRS, at the main recruiting   
site of our study 16% of the 38 patients were found to have asthma compared with 21% in the more 
broadly inclusive CRES study 
20  
which may explain some of the difference in QoL. 
EQ-5D-5L suggests there is a greater impact of CRS as the health index score generated for this group of 
patients was 0.75. We are limited by the lack of UK studies that use the newest version of the EQ-5D (5 
  
 
 
 
 
level version as used in this study) when putting this figure into context. Data from the USA shows  
COPD patients to have an index score of 0.79 
21 
and European data showed a score of 0.69 in patients 4 
months after a stroke
22 
Hence our study would suggest that CRS does impact on quality of life and 
perhaps surprisingly to similar scale as that seen in other chronic disease states. 
 
Health profile reporting shows that many patients are able to continue about their normal activities of 
daily living with the majority reporting a level 1 response of ‘no problem’ with regards to mobility, self- 
care and usual activities. Contrary to this patients were more affected in the domains of pain/discomfort 
and anxiety/depression with a larger percentage reporting a level 2 (slight problems) or 3 (moderate 
problems). This is of interest on two accounts, first similar to the aforementioned studies there appears to 
be a psychological aspect to the disease that is not particularly highlighted with the SF-12. Secondly, that 
pain/discomfort is reported in a significant number of patients in line with previous studies which have 
shown that 70% of patients with CRSsNPs undergoing sinus surgery report facial pain
23 
alongside higher 
rates of anxiety and depression 
10
. 
It is interesting that the health index score for our UK cohort of patients undergoing a trial of medical 
treatment suggests greater disease burden than a US cohort of patients who have already failed medical 
therapy and have been selected for surgery (index value of 0.81)
9 
but may reflect differences in accepted 
maximum medical therapy between the two nations. In our feasibility study, 50% of patients improved 
with maximal medical treatment 
13
, and therefore one would expect those selected for surgery in the US 
study to be a more severely affected subgroup. Of note, surgical intervention rates in the US are 
significantly higher than in the UK and may reflect lower thresholds for surgery in the US. In addition it 
may also reflect differences in primary care treatment, such that only more severely affected patients are 
treated within secondary care in the UK. This highlights the importance of evaluating health utility in a 
UK cohort and puts the disease in perspective as compared to other commonly encountered chronic 
disease states. 
  
 
 
 
 
Strengths of this study 
 
This study data is useful in two ways, firstly it provides a reference generic QOL measurement in UK 
patients with CRS for future researchers. We have shown the mean SNOT-22 scores to be in line with a 
large UK epidemiological study 
24 
and hence the data provided here can be used  as  a benchmark for 
future patient cohorts. Additionally they allow comparison of CRSsNPs with other chronic disease states, 
the health index scores obtained from the EQ-5D data indicate it has significant impact on patients. The 
health index score generated for this group of patients gives a simple value in which to compare other  
CRS cohorts internationally but also allows comparison with other chronic disease states. 
 
A recent European study found a prevalence of CRS to be at 11% but despite comparable prevalence rates 
to both asthma and diabetes with similar negative impact upon quality of life and economic burden, there 
is a considerable disparity in the research funding and publications rates between the conditions. We 
would hope that the data would support future research into treatments for CRS on par with that for 
chronic respiratory disease and back pain. Making comparisons to other chronic conditions puts the plight 
of CRS patients into perspective. 
 
The fact that patients included in this study presented to a specific rhinology clinic (rather than a general 
ENT outpatient clinic) is a limitation of the study as it means there may be a bias towards those with more 
severe disease. However, due to the similar SNOT-22 scores to other CRSsNPs patients in larger cohorts  
24 25 
and because the exclusion criteria prevented those who had tried previous maximal medical therapy 
from joining the study (therefore  unlikely to  have  had  recalcitrant  disease),     we  believe  the  patients 
included here to be representative. Time from diagnosis will have varied in the group and some patients 
 
within the cohort will have received longer courses of intranasal steroids than others; whilst this may 
 
influence  the  baseline  readings  in  our  study it is likely to  reflect the  general cohort  of  CRS  patients 
 
worldwide who have often taken over-the-counter regimes alongside physician prescribed medications 
  
 
 
 
 
during their disease pathway. Other limitations include the small sample size and lack of data from 
patients with CRS with nasal polyposis, which should be performed in the future. 
 
 
Clinical applicability of the study 
 
Index value generated from the EQ-5D questionnaire shows UK patients with CRSsNPs to be negatively 
affected with regards to their HRQoL with scores in line with other chronic disease states. We would 
advise using the EQ-5D-5L questionnaire, as a quick and reliable method of assessing HRQoL in future 
studies using CRS cohorts. The SF-12 has not been shown on this occasion to be particularly useful and  
as such we would not advise it is used in CRS related studies but perhaps replaced by the SF-36 as used in 
other studies. 
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Figure 1a-d. Association between SNOT-22 scores and EQ-5D-5L VAS and utility scores and SF-12 
MCS and PCS scores 
  
 
 
 
 
Table 1: Percentage of patients reporting each level (no problems = level 1, extreme problem = level 5) of 
the 5 dimension components of the EQ-5D 
 
Table 1 
% of 
patients 
reporting 
Mobility Self-care Usual 
activities 
Pain/discomfort Anxiety/depression 
level 1 69.23 90.38 60.46 32.69 57.69 
level 2 11.54 0 15.38 30.77 21.15 
level 3 9.62 7.69 15.38 25 17.31 
level 4 9.62 1.92 5.77 9.62 1.92 
level 5 0 0 0 1.92 1.92 
  
 
 
 
 
Table 2: Physical Component Scores (PCS) and Mental Component Scores (MCS) of the SF12 
Questionnaire. 
 
 PCS MCS 
Current study 46.53 46 
Benign Prostatic Hypertrophy
17
 44.57 44.08 
Congestive heart failure
17
 31.47 38.36 
Parkinson’s17 23.30 29.09 
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Figure 1a. Association between SNOT-22 scores and EQ-5D-5L VAS 
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Figure 1b. Association between SNOT-22 scores and EQ-5D-5L utility scores 
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Figure 1c. Association between SNOT-22 scores SF-12 MCS scores 
70x51mm (300 x 300 DPI) 
  
 
For 
Peer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1d. Association between SNOT-22 scores SF-12 PCS scores 
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